Safety and Efficacy Study of Budesonide (Pulmicort®) Turbuhaler® in Japanese Children With Bronchial Asthma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00509028
First received: July 17, 2007
Last updated: July 24, 2012
Last verified: July 2012
  Purpose

This study will include the patients who are Japanese children with bronchial asthma aged 5 years to 15 years old and have completed the Phase III study (Study code: D5254C00769) at about 29 centres. To investigate the safety of budesonide Turbuhaler® with a daily dose of 100 µg to 800 µg for 54 weeks treatment including the prior 6 weeks Phase III study (Study D5254C00769, NCT00504062) as compared with conventional therapy in Japanese children with bronchial asthma in need of inhaled glucocorticosteroid treatment.


Condition Intervention Phase
Asthma
Drug: Budesonide
Drug: Conventional Asthma Therapy
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label, Multi-center, Long Term Study to Investigate the Safety and Efficacy of Budesonide Turbuhaler® Treatment for 48 Weeks (Following 6 Weeks Phase III Study) in Japanese Children With Bronchial Asthma Aged 5 Years to 15 Years Old

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Number of Patients With Adverse Events (AEs). [ Time Frame: 54 weeks ] [ Designated as safety issue: No ]
    AEs were defined as undesirable medical conditions or deteriorations of a pre-existing medical condition following/during exposure. All Serious AEs, AEs leading to withdrawal, Other relevant AE were recorded.


Secondary Outcome Measures:
  • Number of Patients With Abnormal Clinical Laboratory Test Values. [ Time Frame: 54 weeks ] [ Designated as safety issue: No ]

    Analysis of haematological, clinical chemistry and urynalysis variables were performed.

    Haematology variables: erythrocytes, haemoglobin, haematocrit, leucocyte count, leucocyte different count (neutrophils, eosinophils, basophils, lymphocytes, monocytes), platelet count.

    Clinical chemistry measurements: aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin, albumin, creatinine,sodium, potassium, total protein, blood urea nitrogen.

    Urinalysis variables: protein, glucose, urobilinogen, occult.


  • Number of Patients With Abnormal Vital Sign Values for the Following Variables: Blood Pressure (Sitting) and Pulse Rate (Sitting), as Judged by the Investigator [ Time Frame: 54 weeks ] [ Designated as safety issue: No ]
  • Number of Patients With Abnormal Plasma Cortisol Values. [ Time Frame: 54 weeks ] [ Designated as safety issue: No ]
    Cut-off value of cortisol is defined as 4 mcg/dL.

  • Height [ Time Frame: Baseline and 54 weeks ] [ Designated as safety issue: No ]
    Height, change from baseline calculated as (height at last visit - height at randomization)

  • Weight [ Time Frame: Baseline and 54 weeks ] [ Designated as safety issue: No ]
    Weight, change from baseline calculated as (weight at last visit - weight at randomization)

  • Morning Peak Expiratory Flow (PEF) Percentage of Predicted Normal [ Time Frame: 54 weeks ] [ Designated as safety issue: No ]
    Change in PEF percent of predicted normal calculated as (PEF percent predicted normal at last visit - PEF percent predicted normal at randomization).

  • Change From Baseline of Respiratory Condition at Asthma Attacks (Daytime) [ Time Frame: Baseline and 54 weeks ] [ Designated as safety issue: No ]

    Change in respiratory condition at asthma attacks (daytime) from baseline to last visit. Scale: 0 - 4.

    0 = None. 1 = Mild. 2 = Moderate. 3= Severe. 4 = Respiratory insufficiency


  • Change From Baseline of Respiratory Condition at Asthma Attacks (Nighttime) [ Time Frame: Baseline and 54 weeks ] [ Designated as safety issue: No ]

    Change in respiratory condition at asthma attacks (nighttime) from baseline calculated as (respiratory condition at asthma attacks (nighttime) at last visit - respiratory condition at asthma attacks (night-time) at randomization).

    Scale: 0 - 4. 0 = None. 1 = Mild. 2 = Moderate. 3= Severe. 4 = Respiratory insufficiency.


  • Change From Baseline of Use of Inhaled Short-acting B-2 Agonist (Daytime) [ Time Frame: Baseline and 54 weeks ] [ Designated as safety issue: No ]
    Change in use of inhaled short-acting B-2 agonist (daytime) from baseline calculated as (use of inhaled short-acting B-2 agonist (daytime) at last visit - use of inhaled short-acting B-2 agonist (daytime) at randomization)

  • Change From Baseline of Use of Inhaled Short-acting B-2 Agonist (Night-time) [ Time Frame: Baseline and 54 weeks ] [ Designated as safety issue: No ]
    Change in use of inhaled short-acting B-2 agonist (night-time) from baseline calculated as (use of inhaled short-acting B-2 agonist (night-time) at last visit - use of inhaled short-acting B-2 agonist (night-time) at randomization)

  • Change From Baseline in Disturbance of Daily Activities [ Time Frame: Baseline and 54 weeks ] [ Designated as safety issue: No ]

    Change in disturbance of daily activities from baseline calculated as (disturbance of daily activities at last visit - disturbance of daily activities at randomization).

    Frequency of disturbance of daily activity was assessed using 3- grade scale (normal, almost able, unable).


  • Change From Baseline in Disturbance of Night-time Sleep [ Time Frame: Baseline and 54 weeks ] [ Designated as safety issue: No ]

    Change in disturbance of night-time sleep from baseline calculated as (disturbances of night-time sleep at last visit - disturbances of night-time sleep at randomization).

    Frequency of disturbance of night- time sleep was assessed using 3- grade scale (normal, almost able, unable).


  • Forced Expiratory Volume in One Second (FEV1) Percentage of Predicted Normal Change From Baseline [ Time Frame: 54 weeks ] [ Designated as safety issue: No ]
    Forced Expiratory Volume in one second (FEV1) percentage of predicted normal change from baseline calculated as: 100 * (FEV1 at last visit - FEV1 at randomization)/predicted normal FEV1).


Enrollment: 241
Study Start Date: December 2006
Study Completion Date: October 2008
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BUD - Budesonide
Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily
Drug: Budesonide
Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily
Other Name: Pulmicort® Turbuhaler®
Active Comparator: CONV - Conventional Asthma Therapy
Conventional Asthma Therapy - according to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.
Drug: Conventional Asthma Therapy
According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.

  Eligibility

Ages Eligible for Study:   5 Years to 15 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient who complete preceding the Phase III study and provide a signed written informed consent by patient's legal representative at Visit 1 or 4 weeks prior to Visit 1 of the study. A signed written informed assent should also be obtained from the patients themselves as much as possible
  • When the investigator will obtain the signed written informed consent of Phase III study (D5254C00769) from patient's legal representative, the investigator will also provide the information of this study

Exclusion Criteria:

  • Respiratory infections that, in the opinion of the investigator(s), may affect the efficacy evaluation e.g., lower airways infection such as pneumonia, infection with no available effective antimicrobial drugs or with deep seated mycosis
  • Concurrent serious diseases of liver, kidney, heart or other complications which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or may influence the results of the study, or the patient's ability to participate in the study. Any clinically relevant abnormal findings in vital sign or physical examination at Visit 1 in this study, which in the opinion of the investigator may put the patient at risk because of his/her participation in the study.
  • Pregnant or possible pregnancy or planning to become pregnant during the study period
  • Other subjects who are considered inappropriate to participate in this study judged by the investigator
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00509028

Locations
Japan
Research Site
Takizawa, Iwate, Japan
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Lars-Goran Carlsson, MD AstraZeneca R&D Lund
  More Information

No publications provided

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00509028     History of Changes
Other Study ID Numbers: D5254C00006
Study First Received: July 17, 2007
Results First Received: October 6, 2009
Last Updated: July 24, 2012
Health Authority: Japan: Ministry of Health, Labor and Welfare

Keywords provided by AstraZeneca:
Asthma
Bronchial

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Budesonide
Anti-Inflammatory Agents
Therapeutic Uses
Pharmacologic Actions
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists

ClinicalTrials.gov processed this record on August 28, 2014